DG2-23745-85034
2 vaccinations
4 coded responses
24 check-ins
4 free-text entries
2 call cases
- Sex
- Male
- Age at first dose
- 56-60
- ZIP prefix
- 840 / UT
- Registered
- 2021-03-16
- Relationship
- Self
- Race
- N/A
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-03-16
Registered in v-safe
-
2021-03-16
Dose 1 — Pfizer-BioNTech
- 2021-03-16
- 2021-03-17
- 2021-03-18
- 2021-03-19
- 2021-03-20
- 2021-03-22
- 2021-03-23
- 2021-03-30
-
2021-04-06
Dose 2 — Pfizer-BioNTech
- 2021-04-06
- 2021-04-07
- 2021-04-08
- 2021-04-09
- 2021-04-10
- 2021-04-11
- 2021-04-12
- 2021-04-13
-
2021-04-20
Survey response — day 14, dose 2MedDRA: Headache, Pain — Feeling: FairFree text: Headaches and some minor aches and pain. Nothing seriousMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-04-27
-
2021-05-04
Survey response — day 28, dose 2MedDRA: Excessive granulation tissue, Macular oedema, Office visit, Ophthalmic migraine, Scar, Visual impairment — Feeling: Good · Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: Symptoms: Continuing ocular migraine symptoms well beyond customary duration. Saw ophthalmologist about diminished vision. Dr Identified macular swelling and residual scar tissue. Cause unknown. · Healthcare visit (other): Complete eye exam, retinal scans and photos.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-05-04
Report sent to call center — day 28, dose 2Get care from a doctor or other healthcare professional1 call case(s)
- 2021-05-11
- 2021-05-19
- 2021-07-06
-
2021-10-05
Survey response — 6 months, dose 2MedDRA: Hypertension, Macular oedema, Macular scar, Office visit, Ophthalmic migraine, Optical coherence tomography abnormal, Visual impairment — Feeling: Fair · Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitFree text: Symptoms: High blood pressure and now taking 100mg Lozartin. Increase ocular migraine events. Retina/ macula scans discovered some swelling and scarring on both right and left macula with no known reason or cause. Some small center of vision voids discovered · Healthcare visit (other): Multiple visits to ophthalmologistMedDRA releases: 2024-11 · check-in free text available
-
2021-10-05
Report sent to call center — 6 months, dose 2Be unable to do your normal daily activities · Get care from a doctor or other healthcare professionalOutpatient clinic or urgent care clinic visit · 1 call case(s)
-
2021-10-06
Call successfulNot applicable (accidental reporting or does not believe symptoms are related to vaccine)
-
2022-04-06
Survey response — 12 months, dose 2MedDRA: COVID-19, SARS-CoV-2 test positive — Feeling: Fair · Be unable to work or attend schoolFree text: Was tested and confirmed infected with COVID-19 on October 29, 2021MedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-03-16 | Pfizer-BioNTech | |
| 2 | 2021-04-06 | Pfizer-BioNTech |
Call center
2 call center cases
2 successful
Free text
Release 7 — day 14, dose 2
Symptoms: Headaches and some minor aches and pain. Nothing serious
Release 8 — day 28, dose 2
Symptoms: Continuing ocular migraine symptoms well beyond customary duration. Saw ophthalmologist about diminished vision. Dr Identified macular swelling and residual scar tissue. Cause unknown.
Healthcare visit (other): Complete eye exam, retinal scans and photos.
Release 10 — 6 months, dose 2
Symptoms: High blood pressure and now taking 100mg Lozartin. Increase ocular migraine events. Retina/ macula scans discovered some swelling and scarring on both right and left macula with no known reason or cause. Some small center of vision voids discovered cut off by CDC
Healthcare visit (other): Multiple visits to ophthalmologist
Release 11 — 12 months, dose 2
Symptoms: Was tested and confirmed infected with COVID-19 on October 29, 2021
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| HCVO | Office visit | ✓ | ✓ | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SD | Excessive granulation tissue | ○ | ✓ | ○ |
| SD | Headache | ✓ | ✓ | ✓ |
| SD | Hypertension | · | · | ✓ |
| SD | Macular oedema | ✓ | ✓ | ✓ |
| SD | Macular scar | · | · | ✓ |
| SD | Office visit | ✓ | · | ✓ |
| SD | Ophthalmic migraine | ✓ | ✓ | ✓ |
| SD | Optical coherence tomography abnormal | · | · | ✓ |
| SD | Pain | ✓ | ✓ | ✓ |
| SD | SARS-CoV-2 test positive | · | · | ✓ |
| SD | Scar | ✓ | · | ✓ |
| SD | Visual impairment | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release